'Not for Human Consumption' Did Not Save SARMs

what exactly did FDA say about the 'research compound' labeling?

FDA didn't dispute that the label read 'RESEARCH COMPOUND' and 'NOT FOR HUMAN CONSUMPTION' on some of the products it reviewed — it found the label beside the point. In its December 12, 2025 letter to Prime Sports Nutrition (CMS 719433), the agency wrote that 'evidence obtained from your product labeling, including your website, establishes that your products are intended to be drugs for human use.'

That single sentence carries the whole doctrine.

The finding runs through FDA's ordinary drug-classification chain: intended use under section 201(g)(1) of the Food, Drug and Cosmetic Act, new-drug status under section 201(p), and a sales violation under sections 301(d) and 505(a). None of that chain turns on the printed label — the label is one exhibit FDA reads alongside the site, the checkout flow, and the surrounding sales copy.

how does website marketing copy establish intended use against a label disclaimer?

Under 21 CFR 201.128, the legal test for classifying a product as a drug — its 'intended use' — looks at the objective intent of whoever controls the labeling, and that intent can be shown by advertising copy, oral statements, or simply the circumstances of how the product moves through distribution. A disclaimer printed on the bottle is one document inside that record, not the whole record.

FDA applied the identical doctrine to a different research-labeled category on March 31, 2026, in a letter to Gram Peptides over retatrutide and tirzepatide, a pairing we cover in Peptide Advertising Rules: BPC-157, GLP-1 & the FDA. There, the agency went past mechanism-of-action copy: it held that selling bacteriostatic water — sterile water used to dissolve a peptide before injection — alongside a compound that needs reconstitution was itself evidence the product was meant for a person, not a lab bench. A seller who assumes that skipping dosage instructions clears the intended-use risk is reading the doctrine too narrowly; bundling the injection-adjacent accessory did the same work a dosing chart would have.

which compounds were named as unapproved new drugs in that letter?

FDA named four compounds in the Prime Sports Nutrition letter, split across two mechanism classes but sold to the same audience through the same funnel. All four carried research-only labeling, and none of the four disclaimers changed the outcome.

Three of the four are SARMs; the fourth works on a separate hormonal pathway entirely.

what safety findings did FDA attach to the enforcement action?

FDA didn't rest the letter on labeling alone — it wrote safety findings directly alongside the drug-status finding, warning of 'the potential to increase the risk of heart attack and stroke.' That sentence sits in the same letter as the agency's finding on liver toxicity, so the safety record and the drug-status finding were built together, not filed separately.

Liver toxicity was the other named risk.

For an advertiser buying media against one of these compounds, the safety language matters more than the drug-status language, because it travels with the product rather than with any single ad. A letter naming liver toxicity and cardiovascular risk becomes part of the product's public record the moment FDA posts it, and every reseller carrying that SKU — private label, dropship, or affiliate — inherits the same finding whether or not your own landing page ever mentions it.

how many hormone-adjacent sellers appear in the recent warning-letter record?

At least seven sellers of SARMs- or testosterone-adjacent products turn up in FDA's warning-letter index between 2022 and 2026, which tells you this is a recurring enforcement lane rather than one company's bad luck.

We could not confirm the specific claim language in six of these seven letters — only the Prime Sports Nutrition and Gram Peptides letters were read in full for this piece — and confirming the rest would mean pulling each PDF from FDA's warning-letter index directly. What we can confirm is the cadence: a new letter in this cluster roughly every few months since 2022, with no sign of it slowing in 2026.

• Indiangoods.shop — June 17, 2026
• Dynamic Health Group dba SARMS AMERICA — December 12, 2025
• HIS Enterprise Inc dba Adam's Secret USA, LLC — January 10, 2023
• Warrior Labz SARMS — June 12, 2023
• 11-11-11 Brands — November 16, 2022
• Elite Supplement Center LLC — July 6, 2022
• Thriftmaster Texas LLC — 2022

where does Google's unapproved substances policy hit this category regardless of legality?

Google's Unapproved substances policy hits SARMs and hormone-adjacent products on two separate grounds, and either one alone is enough to lose the account. The policy bars 'Products that imply they're as effective as prescription drugs or controlled substances,' which covers the standard legal-alternative pitch. It separately bars 'Products that have been subject to any government or regulatory action or warning' — meaning a public FDA letter becomes an independent, permanent disqualifier on its own.

Fixing the ad copy afterward does not undo this.

We checked Google's policy text against the same enforcement facts used on this page and found the two rules line up cleanly: the government-action clause and FDA's warning-letter stream feed each other directly. Because the disqualifier attaches to the product rather than the page, a new landing page selling the same compound inherits the same problem the old one had.

why does positioning a product as prescription-equivalent trigger a separate prohibition?

You trip this prohibition the moment your copy claims prescription-equivalence, and you don't need any FDA action to exist first for it to apply. That's what separates this clause from the government-action clause covered above — a page can violate it on day one, before any regulator has looked at the product, just by writing 'works like Anavar' or 'legal alternative to Winstrol.'

The same 'implies equivalence to a controlled substance' logic shows up on affiliate networks well beyond Google, wherever a network reviews landing pages before approving a link — a pattern we've documented for ClickBank's compliance rules. A page selling a SARM as 'what bodybuilders use instead of prescription steroids' fails that review regardless of which network hosts it.

The comparison is the violation, not the compound.

what does a disclaimer actually accomplish, if not this?

A disclaimer accomplishes very little once a product is being sold, priced and shipped to individual buyers, because both FDA and FTC read intent from the whole distribution picture rather than from one printed line. FTC's own Health Products Compliance Guidance makes the same point in a different context: a disclaimer that runs directly against the claim sitting next to it does not cancel that claim out, even when the disclaimer is printed clearly. That is the same logic FDA used to set aside 'not for human consumption' in the Prime Sports Nutrition letter.

What a research-use disclaimer can still do, if the rest of the operation actually matches it, is support a genuine research sale — a chemical supplier shipping bulk compound to a university lab or a contract manufacturer, with no consumer storefront, no dosing chart, no bodybuilding-forum testimonials, and no single-bottle retail packaging. FDA's enforcement pattern draws that line by circumstance rather than by wording: the products in these letters were sold in bottle counts sized for one person, priced per bottle rather than per kilogram, and marketed on pages built around benefit language instead of a chemical data sheet. Once those circumstances point at a consumer, no sentence on the label reverses the reading — which is the same principle we set out in FDA Rules the Label. FTC Rules Your Ad.: the label is judged alongside everything else the buyer sees, never instead of it.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Sleep Supplement Ads: Winning Angles Beyond Melatonin, Collagen Supplement Ads: The Angles Scaling in 2026, Female Libido Offers: Ads, Angles and Payouts 2026, Parasite Cleanse Offers: Inside the 2026 Detox Ad Wave, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.